Journal profile · Biochemistry & Molecular Biology
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
ISSN 0304-419X · eISSN 1879-2561 · Elsevier · NETHERLANDS · Quarterly
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER: CAS Zone 2 · Medicine (2025 upgraded edition, Top journal); impact factor 11.18; hybrid open access; APC about USD 5,070; median 130 days to acceptance (106 articles, last 24 months); community-reported acceptance: about 50%; 266 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER is published by Elsevier and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Cancer, Hypoxia, and Metabolism, Epigenetics and DNA Methylation and Cancer Cells and Metastasis, together about 20.3% of its articles. Its main subfields are Molecular Biology and Oncology. (generated from OpenAlex topic counts and CAS ranking data)
BBA Reviews on Cancer covers the whole field of the biology and biochemistry of cancer, emphasizing oncogenes and tumor suppressor genes, growth-related cell cycle control signalling, carcinogenesis mechanisms, cell transformation, immunologic control mechanisms, genetics of human (mammalian) cancer, control of cell proliferation, genetic and molecular control of organismic development, rational anti-tumor drug design. In short, the journal presents critical invited reviews on new developments in cancer investigation at the molecular level.
Source: LetPub
Research area (LetPub): Biochemistry & Molecular Biology
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology7.3%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology6.8%
- Cancer Cells and MetastasisMedicine6.2%
- Cancer-related Molecular PathwaysMedicine6.1%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance5.2%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology5.1%
- Cancer Immunotherapy and BiomarkersMedicine5.1%
- Human auditory perception and evaluationEngineering4.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Biochemistry & Molecular Biology | Zone 2 |
| Minor | Biophysics | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Biochemistry & Molecular Biology | Zone 2 |
| Minor | Biophysics | Zone 1 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Biochemistry & Molecular Biology | Zone 2 |
| Minor | Biophysics | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 11.18LetPub ·
- CiteScore 2026-06
- 14.1LetPub ·
- SJR 2026-06
- 2.88LetPub ·
- SNIP 2026-06
- 2.02LetPub ·
- h-index
- 129LetPub ·
- h-index
- 209OpenAlex ·
- i10-index
- 1,871OpenAlex ·
- 2-year mean citedness
- 7.55OpenAlex ·
- Self-citation rate
- 1.8%LetPub ·
- Share of gold OA articles
- 26.85%LetPub ·
Volume
- Articles per year
- 258LetPub ·
Articles by year OpenAlex count · 2,704 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 193 | 61 | 185 |
| 2025 | 266 | 84 | 1,648 |
| 2024 | 163 | 67 | 2,860 |
| 2023 | 174 | 68 | 5,456 |
| 2022 | 136 | 42 | 5,309 |
| 2021 | 141 | 54 | 9,102 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
130 daysMedian, submission to acceptance · P25–P75 107 days – 173 days
- Acceptance to online
- median 2 days (106 articles)
- Submission to online
- median 131 days
- Sample
- 106 articles with submission and acceptance dates (543 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 1 monthLetPub ·
- Average acceptance (community reports)
- 50%LetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 5,070 / EUR 4,740 / GBP 4,060 / JPY 628,830 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- NETHERLANDS
- Language
- Dutch
- Frequency
- Quarterly
- ISSN
- 0304-419X
- Electronic ISSN
- 1879-2561
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
What CAS zone is BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER in?
In the 2025 upgraded edition of the CAS Journal Ranking, BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER is in Zone 2 of Medicine, and in Zone 2 of the minor category Biochemistry & Molecular Biology / Biophysics / Oncology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER?
The latest impact factor listed by LetPub is 11.18; CiteScore 14.1, h-index 209.
How long does peer review take at BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER?
Based on the dates recorded on 106 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 130 days (interquartile range 107–173 days); authors report an average review time of about 1 month; the community-reported acceptance is “about 50%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER?
According to LetPub and DOAJ records, BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER is indexed in SCIE and Scopus.
Is BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER open access, and what is the APC?
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER is a hybrid journal. For open-access publication: APC about USD 5,070.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .